Kathryn E Hitchcock, MD, PhD

This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from…

Investigator

Kathryn E Hitchcock

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients…

Investigator

Kathryn E Hitchcock

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV…

Investigators

Roi Dagan, Kathryn E Hitchcock

Status

Accepting Candidates

Ages

18 Years - 99 Years

Sexes

All